rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2020-532-543rsp-2957Research ArticleПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕPROGRESS IN RHEUMATOLOGY IN THE XXI CENTURYПерспективы применения упадацитиниба при ревматоидном артрите и других иммуновоспалительных ревматических заболеванияхThe progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseaseshttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

Насонов Евгений Львович — д.м.н., профессор, академик РАН, научный руководитель ФГБНУ «НИИР им. В.А. Насоновой»

115522, Москва, Каширское шоссе, 34а119991, Москва, ул. Трубецкая, 8, стр. 2 

Evgeniy L. Nasonov

115522, Moscow, Kashirskoe highway, 34A119991, Moscow, Trubetskaya str., 8/2 

nasonov@irramn.ruhttps://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

Лила А.М. — д.м.н., профессор, директор ФГБНУ «НИИР им. В.А. Насоновой»

115522, Москва, Каширское шоссе, 34а125993, Москва, ул. Баррикадная, 2/1, стр. 1 

Aleksander М. Lila

115522, Moscow, Kashirskoe highway, 34A125993, Moscow, Ulitsa Barrikadnaya, 2/1, building 1 

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)Россия“V. A. Nasonova Research Institute of Rheumatology named”; I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Health of RussiaRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссия“V. A. Nasonova Research Institute of Rheumatology named”; Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian FederationRussian Federation202009112020585532543Copyright © Насонов Е.Л., Лила А.М., 20202020Насонов Е.Л., Лила А.М.Nasonov E.L., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2957

Расшифровка механизмов патогенеза ревматоидного артрита в сочетании с разработкой широкого спектра генно-инженерных биологических препаратов относятся к числу крупных достижений медицины XXI в. Новое направление фармакотерапии иммуновоспалительных ревматических заболеваний связано с созданием «таргетных» пероральных лекарственных противовоспалительных препаратов, к которым относятся ингибиторы янус-киназ. Представителем класса этих ингибиторов является упадацитиниб, который зарегистрирован для лечения ревматоидного артрита и проходит клинические испытания при анкилозирующем спондилите, псориатическом артрите и других иммуновоспалительных ревматических заболеваниях. В обзоре представлены новые данные, касающиеся эффективности и безопасности упадацитиниба при ревматоидном артрите.

The explanation of the mechanisms underlying the pathogenesis of rheumatoid arthritis (RA), along with the development of a wide range of biologics (bDMARDs), is among the major achievements of medicine in the 21st century. A new direction in the pharmacotherapy of inflammatory rheumatic diseases is associated with the development of “targeted” oral anti-inflammatory drugs, which include Janus kinase (JAK) inhibitors. One representative of the class of JAK inhibitors is upadacitinib (UPA), which has been registered for the treatment of RA and is undergoing clinical studies in patients with ankylosing spondylitis, psoriatic arthritis, and other inflammatory rheumatic diseases. This review presents new data on the efficacy and safety of UPA in RA.

ревматоидный артритингибиторы JAKупадацитинибrheumatoid arthritisJAK inhibitorsupadacitinibReferencesBaker K.F., Isaacs J.D. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175–187. DOI: 10.1136/annrheumdis-2017-211555Baker K.F., Isaacs J.D. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175–187. DOI: 10.1136/annrheumdis-2017-211555Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409–419. [Nasonov E.L. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(4):409–419 (In Russ.)]. DOI: 10.14412/1995-4484-2017-409-419Nasonov E.L. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(4):409–419 (In Russ.). DOI: 10.14412/1995-4484-2017-409-419Schwartz D.M., Kanno Y., Villarino A., et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. DOI: 10.1038/nrd.2017.201Schwartz D.M., Kanno Y., Villarino A., et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. DOI: 10.1038/nrd.2017.201Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8–16. DOI: 10.14412/1995-4484-2019-8-16Nasonov E.L., Lila A.M. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2019;57(1):8–16 (In Russ.). DOI: 10.14412/1995-4484-2019-8-16Насонов Е.Л., Авдеева А.С., Лила А.М. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть I). Научно-практическая ревматология. 2020;58(1):62–79. DOI: 10.14412/1995-4484-2020-62-79Nasonov E.L., Avdeeva A.S., Lila A.M. Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2020;58(1):6279 (In Russ.). DOI: 10.14412/1995-4484-2020-62-79Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017;77(18):1987–2001. DOI: 10.1007/s40265-017-0835-9Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017;77(18):1987–2001. DOI: 10.1007/s40265-017-0835-9Насонов Е.Л., Лила А.М. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научнопрактическая ревматология. 2020;58(3):304–316. DOI: 10.14412/1995-4484-2020-304-316Nasonov E.L., Lila A.M. Baricitinib: new pharmacotherapy options for rheumatoid arthritis and other immune-mediated inflammatory rheumatic diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2020;58(3):304–316 (In Russ.). DOI: 10.14412/1995-4484-2020-304-316Al-Salama Z.T., Scott L.J. Baricitinib: A review in rheumatoid arthritis. Drugs. 2018;78(7):761–772. DOI: 10.1007/s40265-018-0908-4Al-Salama Z.T., Scott L.J. Baricitinib: A review in rheumatoid arthritis. Drugs. 2018;78(7):761–772. DOI: 10.1007/s40265-018-0908-4Serhal L., Edwards C.J. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15(1):13–25. DOI: 10.1080/1744666X.2019.1544892Serhal L., Edwards C.J. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15(1):13–25. DOI: 10.1080/1744666X.2019.1544892Tanaka Y. A review of upadacitinib in rheumatoid arthritis [published online ahead of print, 2020]. Mod Rheumatol. 2020;1–9. DOI: 10.1080/14397595.2020.1782049Tanaka Y. A review of upadacitinib in rheumatoid arthritis [published online ahead of print, 2020]. Mod Rheumatol. 2020;1–9. DOI: 10.1080/14397595.2020.1782049Villarino A.V., Kanno Y., O’Shea J.J. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384. DOI: 10.1038/ni.3691Villarino A.V., Kanno Y., O’Shea J.J. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384. DOI: 10.1038/ni.3691Hosseini A., Gharibi T., Marofi F., Javadian M., Babaloo Z., Baradaran B. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol. 2020;235(9):5903–5924. DOI: 10.1002/jcp.29593Hosseini A., Gharibi T., Marofi F., Javadian M., Babaloo Z., Baradaran B. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol. 2020;235(9):5903–5924. DOI: 10.1002/jcp.29593Parmentier J.M., Voss J., Graff C., et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23. DOI: 10.1186/s41927-018-0031-xParmentier J.M., Voss J., Graff C., et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23. DOI: 10.1186/s41927-018-0031-xMcInnes I.B., Byers N.L., Higgs R.E., et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. DOI: 10.1186/s13075-019-1964-1McInnes I.B., Byers N.L., Higgs R.E., et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. DOI: 10.1186/s13075-019-1964-1Choy E.H. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953–962. DOI: 10.1093/rheumatology/key339. Erratum in: Rheumatology (Oxford). 2019 Jun 1;58(6):1122.Choy E.H. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953–962. DOI: 10.1093/rheumatology/key339. Erratum in: Rheumatology (Oxford). 2019 Jun 1;58(6):1122.Dowty M.E., Lin T.H., Jesson M.I., et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7(6):e00537. DOI: 10.1002/prp2.537Dowty M.E., Lin T.H., Jesson M.I., et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7(6):e00537. DOI: 10.1002/prp2.537Mohamed M.F., Camp H.S., Jiang P., Padley R.J., Asatryan A., Othman A.A. Pharmacokinetics, safety and tolerability of ABT494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–1558. DOI: 10.1007/s40262-016-0419-yMohamed M.F., Camp H.S., Jiang P., Padley R.J., Asatryan A., Othman A.A. Pharmacokinetics, safety and tolerability of ABT494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–1558. DOI: 10.1007/s40262-016-0419-yVeeravalli V., Dash R.P., Thomas J.A., et al. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Saf. 2020;43(8):711–725. DOI: 10.1007/s40264-020-00938-zVeeravalli V., Dash R.P., Thomas J.A., et al. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Saf. 2020;43(8):711–725. DOI: 10.1007/s40264-020-00938-zKremer J.M., Emery P., Camp H.S., et al. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2016;68(12):28672877. DOI: 10.1002/art.39801Kremer J.M., Emery P., Camp H.S., et al. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2016;68(12):28672877. DOI: 10.1002/art.39801Genovese M.C., Smolen J.S., Weinblatt M.E., et al. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2016;68(12):2857–2866. DOI: 10.1002/art.39808Genovese M.C., Smolen J.S., Weinblatt M.E., et al. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2016;68(12):2857–2866. DOI: 10.1002/art.39808Burmester G.R., Kremer J.M., Van den Bosch F., et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–2512. DOI: 10.1016/S0140-6736(18)31115-2Burmester G.R., Kremer J.M., Van den Bosch F., et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–2512. DOI: 10.1016/S0140-6736(18)31115-2Genovese M.C., Fleischmann R., Combe B., et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–2524. DOI: 10.1016/S0140-6736(18)31116-4Genovese M.C., Fleischmann R., Combe B., et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–2524. DOI: 10.1016/S0140-6736(18)31116-4van Vollenhoven R., Takeuchi T., Pangan A.L., et al. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Activecomparator, Multi-center, Multi-country Trial. Arthritis Rheumatol. 2020;10.1002/art.41384. DOI: 10.1002/art.41384van Vollenhoven R., Takeuchi T., Pangan A.L., et al. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Activecomparator, Multi-center, Multi-country Trial. Arthritis Rheumatol. 2020;10.1002/art.41384. DOI: 10.1002/art.41384Fleischmann R., Pangan A.L., Song I.H., et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019;71(11):1788–1800. DOI: 10.1002/art.41032Fleischmann R., Pangan A.L., Song I.H., et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019;71(11):1788–1800. DOI: 10.1002/art.41032Smolen J.S., Pangan A.L., Emery P., et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECTMONOTHERAPY): a randomised, placebo-controlled, doubleblind phase 3 study [published correction appears in Lancet. 2019 Jun 29;393(10191):2590]. Lancet. 2019;393(10188):2303–2311. DOI:10.1016/S0140-6736(19)30419-2Smolen J.S., Pangan A.L., Emery P., et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECTMONOTHERAPY): a randomised, placebo-controlled, doubleblind phase 3 study [published correction appears in Lancet. 2019 Jun 29;393(10191):2590]. Lancet. 2019;393(10188):2303–2311. DOI:10.1016/S0140-6736(19)30419-2Rubbert-Roth A., Enejosa J., Pangan A.L., Haraoui B., Rischmueller M., Khan N., Zhang Y., Martin N., Xavier R.M. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383(16):1511–1521. DOI: 10.1056/NEJMoa2008250Rubbert-Roth A., Enejosa J., Pangan A.L., Haraoui B., Rischmueller M., Khan N., Zhang Y., Martin N., Xavier R.M. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383(16):1511–1521. DOI: 10.1056/NEJMoa2008250Kameda H., Takeuchi T.., Yamaoka K., Oribe M., Kawano M., Zhou Y., Othman A.A., Pangan A.L., Kitamura S., Meerwein S., Tanaka Y. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebocontrolled phase IIb/III study. Rheumatology (Oxford). 2020;59(11):3303–3313. DOI: 10.1093/rheumatology/keaa084.Kameda H., Takeuchi T.., Yamaoka K., Oribe M., Kawano M., Zhou Y., Othman A.A., Pangan A.L., Kitamura S., Meerwein S., Tanaka Y. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebocontrolled phase IIb/III study. Rheumatology (Oxford). 2020;59(11):3303–3313. DOI: 10.1093/rheumatology/keaa084.Fleischmann R.M., Genovese M.C., Enejosa J.V., et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454–1462. DOI: 10.1136/annrheumdis-2019-215764Fleischmann R.M., Genovese M.C., Enejosa J.V., et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454–1462. DOI: 10.1136/annrheumdis-2019-215764Strand V., Pope J., Tundia N., et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic diseasemodifying antirheumatic drugs: results from SELECT-NEXT [published correction appears in Arthritis Res Ther. 2020 Jun 9;22(1):137]. Arthritis Res Ther. 2019;21(1):272. DOI: 10.1186/s13075-019-2037-1Strand V., Pope J., Tundia N., et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic diseasemodifying antirheumatic drugs: results from SELECT-NEXT [published correction appears in Arthritis Res Ther. 2020 Jun 9;22(1):137]. Arthritis Res Ther. 2019;21(1):272. DOI: 10.1186/s13075-019-2037-1Strand V., Schiff M., Tundia N., et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21(1):263. DOI: 10.1186/s13075-019-2059-8Strand V., Schiff M., Tundia N., et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21(1):263. DOI: 10.1186/s13075-019-2059-8Fleischmann R., Song I.H., Enejosa J., et al. [THU0201]. Longterm safety and effectiveness of upadacitinib or adalimumab in patients with rheumatoid arthritis: results at 72 weeks from the SELECT-COMPARE study. Ann Rheum Dis 2020;79:323. DOI: 10.1136/annrheumdis-2020-eular.1418Fleischmann R., Song I.H., Enejosa J., et al. [THU0201]. Longterm safety and effectiveness of upadacitinib or adalimumab in patients with rheumatoid arthritis: results at 72 weeks from the SELECT-COMPARE study. Ann Rheum Dis 2020;79:323. DOI: 10.1136/annrheumdis-2020-eular.1418Smolen J.S., Emery P., Rigby W., et al. [THU0213]. Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 84 weeks from the SELECT-MONOTHERAPY study. Ann Rheum Dis. 2020;79:331–332. DOI: 10.1136/annrheumdis-2020-eular.961Smolen J.S., Emery P., Rigby W., et al. [THU0213]. Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 84 weeks from the SELECT-MONOTHERAPY study. Ann Rheum Dis. 2020;79:331–332. DOI: 10.1136/annrheumdis-2020-eular.961Van Vollenhoven R., Takeuchi T., Rischmueller M., et al. [THU0217]. Upadacitinib monotherapy in methotrexate-naïve patients with rheumatoid arthritis: results at 72 weeks from SELECT-EARLY. Ann Rheum Dis. 2020;79:334–335. DOI: 10.1136/annrheumdis-2020-eular.1857Van Vollenhoven R., Takeuchi T., Rischmueller M., et al. [THU0217]. Upadacitinib monotherapy in methotrexate-naïve patients with rheumatoid arthritis: results at 72 weeks from SELECT-EARLY. Ann Rheum Dis. 2020;79:334–335. DOI: 10.1136/annrheumdis-2020-eular.1857Van Vollenhoven R., Ostor A., Mysler E., et al. [FRI0138]. The impact of upadacitinib versus methotrexate or adalimumab on individual and composite disease measures in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:651–652. DOI: 10.1136/annrheumdis-2020-eular.1426Van Vollenhoven R., Ostor A., Mysler E., et al. [FRI0138]. The impact of upadacitinib versus methotrexate or adalimumab on individual and composite disease measures in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:651–652. DOI: 10.1136/annrheumdis-2020-eular.1426Kapetanovic M.C., Andersson M., Friedman A., et al. [SAT0145]. Efficacy and safety of upadacitinib monotherapy in mtx-naïve patients with early active ra receiving treatment within 3 months of diagnosis: a post-hoc analysis of the SELECT-EARLY. Ann Rheum Dis. 2020;79:1011. DOI: 10.1136/annrheumdis-2020-eular.1431Kapetanovic M.C., Andersson M., Friedman A., et al. [SAT0145]. Efficacy and safety of upadacitinib monotherapy in mtx-naïve patients with early active ra receiving treatment within 3 months of diagnosis: a post-hoc analysis of the SELECT-EARLY. Ann Rheum Dis. 2020;79:1011. DOI: 10.1136/annrheumdis-2020-eular.1431Buch M., Wells A., Rubbert-Roth A., et al. Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-comparative-analysis-ofupadacitinib-monotherapy-and-upadacitinib-combination-therapyfor-the-treatment-of-rheumatoid-arthritis-from-two-phase-3trials/. Accessed August 20, 2020.Buch M., Wells A., Rubbert-Roth A., et al. Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-comparative-analysis-ofupadacitinib-monotherapy-and-upadacitinib-combination-therapyfor-the-treatment-of-rheumatoid-arthritis-from-two-phase-3trials/. Accessed August 20, 2020.Genovese M.C., Fleischmann R., Blanco R., et al. [OP0029]. Switching between the jak1-selective inhibitor-upadacitinib and adalimumab following initial non-response: clinical and functional outcomes among rheumatoid arthritis patients. Ann Rheum Dis. 2019;78:83–84.Genovese M.C., Fleischmann R., Blanco R., et al. [OP0029]. Switching between the jak1-selective inhibitor-upadacitinib and adalimumab following initial non-response: clinical and functional outcomes among rheumatoid arthritis patients. Ann Rheum Dis. 2019;78:83–84.Peterfy C., Strand V., Genovese M.C., et al. [THU0211]. Radiographic outcomes in patients with rheumatoid arthritis receiving upadacitinib as monotherapy or in combination with methotrexate: results at 2 years from the SELECT-COMPARE and SELECT-EARLY studies. Ann Rheum Dis. 2020;79:330–331. DOI: 10.1136/annrheumdis-2020-eular.1869Peterfy C., Strand V., Genovese M.C., et al. [THU0211]. Radiographic outcomes in patients with rheumatoid arthritis receiving upadacitinib as monotherapy or in combination with methotrexate: results at 2 years from the SELECT-COMPARE and SELECT-EARLY studies. Ann Rheum Dis. 2020;79:330–331. DOI: 10.1136/annrheumdis-2020-eular.1869Weinblatt M., Mysler E., Ostor A., et al. [FRI0140]. Impact of baseline demographics and disease activity on outcomes in patients with rheumatoid arthritis receiving upadacitinib. Ann Rheum Dis. 2020;79:653–654. DOI: 10.1136/annrheumdis-2020-eular.907Weinblatt M., Mysler E., Ostor A., et al. [FRI0140]. Impact of baseline demographics and disease activity on outcomes in patients with rheumatoid arthritis receiving upadacitinib. Ann Rheum Dis. 2020;79:653–654. DOI: 10.1136/annrheumdis-2020-eular.907Насонов Е.Л. Абатацепт при ревматоидном артрите: новая форма, новые механизмы, новые возможности. Научнопрактическая ревматология. 2015;53(5):522–541. DOI: 10.14412/1995-4484-2015-522-541Насонов Е.Л. Абатацепт при ревматоидном артрите: новая форма, новые механизмы, новые возможности. Научнопрактическая ревматология. 2015;53(5):522–541. [Nasonov E.L. Abatacept for rheumatoid arthritis: a novel formulation, new mechanisms, new possibilities. Rheumatology Science and Practice. 2015;53(5):522–541 (In Russ.)] DOI: 10.14412/1995-4484-2015-522-541Schiff M., Weinblatt M.E., Valente R., et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94. DOI: 10.1136/annrheumdis-2013-203843Schiff M., Weinblatt M.E., Valente R., et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94. DOI: 10.1136/annrheumdis-2013-203843Gossec L., Dougados M., Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019. DOI: 10.1136/rmdopen-2014-000019Gossec L., Dougados M., Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019. DOI: 10.1136/rmdopen-2014-000019Cohen S.B., Van Vollenhoven R., Curtis J.R., et al. [THU0197]. Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:319–320. DOI: 10.1136/annrheumdis-2020-eular.2396Cohen S.B., Van Vollenhoven R., Curtis J.R., et al. [THU0197]. Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:319–320. DOI: 10.1136/annrheumdis-2020-eular.2396Winthrop K., Calabrese L., Van den Bosch F., et al. [FRI0141]. Characterization of serious infections with upadacitinib in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:654–655. DOI: 10.1136/annrheumdis-2020-eular.2761Winthrop K., Calabrese L., Van den Bosch F., et al. [FRI0141]. Characterization of serious infections with upadacitinib in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:654–655. DOI: 10.1136/annrheumdis-2020-eular.2761Winthrop K., Nash P., Yamaoka K., et al. [THU0218]. Incidence and risk factors for herpes zoster in rheumatoid arthritis patients receiving upadacitinib. Ann Rheum Dis. 2020;79:335–336. DOI: 10.1136/annrheumdis-2020-eular.2744Winthrop K., Nash P., Yamaoka K., et al. [THU0218]. Incidence and risk factors for herpes zoster in rheumatoid arthritis patients receiving upadacitinib. Ann Rheum Dis. 2020;79:335–336. DOI: 10.1136/annrheumdis-2020-eular.2744Choy E., Mcinnes I., Cush J., et al. [THU0195]. Incidence and risk of venous thromboembolic events among patients with rheumatoid arthritis enrolled in the upadacitinib SELECT clinical trial program. Ann Rheum Dis. 2020;79:317–318. DOI: 10.1136/annrheumdis-2020-eular.2897Choy E., Mcinnes I., Cush J., et al. [THU0195]. Incidence and risk of venous thromboembolic events among patients with rheumatoid arthritis enrolled in the upadacitinib SELECT clinical trial program. Ann Rheum Dis. 2020;79:317–318. DOI: 10.1136/annrheumdis-2020-eular.2897Sepriano A., Kerschbaumer A., Smolen J.S., et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):760–770. DOI: 10.1136/annrheumdis-2019-216653Sepriano A., Kerschbaumer A., Smolen J.S., et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):760–770. DOI: 10.1136/annrheumdis-2019-216653Kerschbaumer A., Sepriano A., Smolen J.S., et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):744–759. DOI: 10.1136/annrheumdis-2019-216656Kerschbaumer A., Sepriano A., Smolen J.S., et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):744–759. DOI: 10.1136/annrheumdis-2019-216656Song G.G., Choi S.J., Lee Y.H. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2019;22(8):1563–1571. DOI: 10.1111/1756-185X.13616Song G.G., Choi S.J., Lee Y.H. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2019;22(8):1563–1571. DOI: 10.1111/1756-185X.13616Lee Y.H., Song G.G. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis [published online ahead of print, 2020 Feb 13]. Relative Wirksamkeit und Sicherheit von Tofacitinib, Baricitinib, Upadacitinib und Filgotinib im Vergleich zu Adalimumab bei Patienten mit aktiver rheumatoider Arthritis [published online ahead of print, 2020 Feb 13]. Z Rheumatol. 2020;10.1007/s00393020-00750-1. DOI: 10.1007/s00393-020-00750-1Lee Y.H., Song G.G. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis [published online ahead of print, 2020 Feb 13]. Relative Wirksamkeit und Sicherheit von Tofacitinib, Baricitinib, Upadacitinib und Filgotinib im Vergleich zu Adalimumab bei Patienten mit aktiver rheumatoider Arthritis [published online ahead of print, 2020 Feb 13]. Z Rheumatol. 2020;10.1007/s00393020-00750-1. DOI: 10.1007/s00393-020-00750-1Jegatheeswaran J., Turk M., Pope J.E. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy. 2019;11(8):737–754. DOI: 10.2217/imt-2018-0178Jegatheeswaran J., Turk M., Pope J.E. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy. 2019;11(8):737–754. DOI: 10.2217/imt-2018-0178Wang F., Sun L., Wang S., et al. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Mayo Clin Proc. 2020;95(7):1404–1419. DOI: 10.1016/j.mayocp.2020.01.039Wang F., Sun L., Wang S., et al. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Mayo Clin Proc. 2020;95(7):1404–1419. DOI: 10.1016/j.mayocp.2020.01.039Ho Lee Y., Gyu Song G. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. J Clin Pharm Ther. 2020;45(4):674–681. DOI: 10.1111/jcpt.13142Ho Lee Y., Gyu Song G. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. J Clin Pharm Ther. 2020;45(4):674–681. DOI: 10.1111/jcpt.13142Song G.G., Lee Y.H. Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol. 2020;79(1):103–111. DOI: 10.1007/s00393-019-0601-3Song G.G., Lee Y.H. Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol. 2020;79(1):103–111. DOI: 10.1007/s00393-019-0601-3Bechman K., Subesinghe S., Norton S., et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(10):1755–1766. DOI: 10.1093/rheumatology/kez087Bechman K., Subesinghe S., Norton S., et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(10):1755–1766. DOI: 10.1093/rheumatology/kez087Pharmacoeconomic Review Report: Upadacitinib (Rinvoq): (AbbVie). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2020.Pharmacoeconomic Review Report: Upadacitinib (Rinvoq): (AbbVie). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; March 2020.Pope J., Sawant R., Tundia N., et al. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Adv Ther. 2020;37(5):2356–2372. DOI: 10.1007/s12325-020-01303-3Pope J., Sawant R., Tundia N., et al. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Adv Ther. 2020;37(5):2356–2372. DOI: 10.1007/s12325-020-01303-3Edwards C., Sawant R., Du E., et al. [THU0168]. A matchingadjusted indirect comparison (MAIC) of upadacitinib versus tofacitinib in csdmard-ir patients with moderate to severe rheumatoid arthritis (RA). Ann Rheum Dis. 2019;78:358. DOI: 10.1136/annrheumdis-2019-eular.7189Edwards C., Sawant R., Du E., et al. [THU0168]. A matchingadjusted indirect comparison (MAIC) of upadacitinib versus tofacitinib in csdmard-ir patients with moderate to severe rheumatoid arthritis (RA). Ann Rheum Dis. 2019;78:358. DOI: 10.1136/annrheumdis-2019-eular.7189van der Heijde D., Strand V., Tanaka Y., et al. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis Rheumatol. 2019;71(6):878–891. DOI: 10.1002/art.40803van der Heijde D., Strand V., Tanaka Y., et al. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis Rheumatol. 2019;71(6):878–891. DOI: 10.1002/art.40803Strand V., Kremer J.M., Gruben D., Krishnaswami S., Zwillich S.H., Wallenstein G.V. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2017;69(4):592–598. DOI: 10.1002/acr.23004Strand V., Kremer J.M., Gruben D., Krishnaswami S., Zwillich S.H., Wallenstein G.V. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2017;69(4):592–598. DOI: 10.1002/acr.23004van Vollenhoven R.F., Fleischmann R., Cohen S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis [published correction appears in N Engl J Med. 2013 Jul 18;369(3):293]. N Engl J Med. 2012;367(6):508–519. DOI: 10.1056/NEJMoa1112072van Vollenhoven R.F., Fleischmann R., Cohen S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis [published correction appears in N Engl J Med. 2013 Jul 18;369(3):293]. N Engl J Med. 2012;367(6):508–519. DOI: 10.1056/NEJMoa1112072Fleischmann R., Mysler E., Hall S., et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-tohead, randomised controlled trial. Lancet. 2017;390(10093):457–468. DOI: 10.1016/S0140-6736(17)31618-5Fleischmann R., Mysler E., Hall S., et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-tohead, randomised controlled trial. Lancet. 2017;390(10093):457–468. DOI: 10.1016/S0140-6736(17)31618-5Dougados M., van der Heijde D., Chen Y.C., et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study [published correction appears in Ann Rheum Dis. 2017 Sep;76(9):1634]. Ann Rheum Dis. 2017;76(1):88–95. DOI: 10.1136/annrheumdis-2016-210094Dougados M., van der Heijde D., Chen Y.C., et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study [published correction appears in Ann Rheum Dis. 2017 Sep;76(9):1634]. Ann Rheum Dis. 2017;76(1):88–95. DOI: 10.1136/annrheumdis-2016-210094Taylor P.C., Keystone E.C., van der Heijde D., et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652–662. DOI: 10.1056/NEJMoa1608345Taylor P.C., Keystone E.C., van der Heijde D., et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652–662. DOI: 10.1056/NEJMoa1608345Li Z., Hu J., Bao C., et al. [SAT0218]. Efficacy and safety of baricitinib in mtx-ir patients with rheumatoid arthritis: 52 week results from a phase 3 study (RA-BALANCE). Ann Rheum Dis. 2018;77:969–970. DOI: 10.1136/annrheumdis-2018-eular.1983Li Z., Hu J., Bao C., et al. [SAT0218]. Efficacy and safety of baricitinib in mtx-ir patients with rheumatoid arthritis: 52 week results from a phase 3 study (RA-BALANCE). Ann Rheum Dis. 2018;77:969–970. DOI: 10.1136/annrheumdis-2018-eular.1983Bechman K., Subesinghe S., Norton S., et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(10):1755–1766. DOI: :10.1093/rheumatology/kez087Bechman K., Subesinghe S., Norton S., et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(10):1755–1766. DOI: :10.1093/rheumatology/kez087Smolen J.S., Landewé R.B.M., Bijlsma J.W.J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. DOI: 10.1136/annrheumdis-2019-216655Smolen J.S., Landewé R.B.M., Bijlsma J.W.J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. DOI: 10.1136/annrheumdis-2019-216655van der Heijde D., Song I.H., Pangan A.L., et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019; 394(10214):2108–2117. DOI: 10.1016/S0140-6736(19)32534-6van der Heijde D., Song I.H., Pangan A.L., et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019; 394(10214):2108–2117. DOI: 10.1016/S0140-6736(19)32534-6Kiltz U., Sieper J., Deodhar A., et al. [THU0375]. Improvements in global functioning and health-related quality of life and their association with disease activity and functional improvement in patients with active ankylosing spondylitis treated with upadacitinib: results from the select-axis 1 trial. Ann Rheum Diseases. 2020;79:420–421. DOI: 10.1136/annrheumdis-2020-eular.857Kiltz U., Sieper J., Deodhar A., et al. [THU0375]. Improvements in global functioning and health-related quality of life and their association with disease activity and functional improvement in patients with active ankylosing spondylitis treated with upadacitinib: results from the select-axis 1 trial. Ann Rheum Diseases. 2020;79:420–421. DOI: 10.1136/annrheumdis-2020-eular.857Mcinnes I., Anderson J., Magrey M., et al. [LB0001]. Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to nonbiologic disease-modifying anti-rheumatic drugs (SELECT-PsA-1): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:16–17. DOI: 10.1136/annrheumdis-2020-eular.6727Mcinnes I., Anderson J., Magrey M., et al. [LB0001]. Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to nonbiologic disease-modifying anti-rheumatic drugs (SELECT-PsA-1): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:16–17. DOI: 10.1136/annrheumdis-2020-eular.6727Genovese M.C., Lertratanakul A., Anderson J., et al. [OP0223]. efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-2): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:139. DOI: 10.1136/annrheumdis-2020-eular.1229Genovese M.C., Lertratanakul A., Anderson J., et al. [OP0223]. efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-2): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:139. DOI: 10.1136/annrheumdis-2020-eular.1229Насонов Е.Л. Метотрексат при ревматоидном артрите — 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421–433. DOI: 10.14412/1995-4484-2015-421-433Nasonov E.L. Methotrexate in rheumatoid arthritis — 2015: new facts and ideas. Rheumatology Science and Practice. 2015;53(4):421–433 (In Russ.). DOI: 10.14412/1995-4484-2015-421-433Chatzidionysiou K., Sfikakis P.P. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. RMD Open. 2019;5(2):e000993. Published 2019 Jul 27. DOI: 10.1136/rmdopen-2019-000993Chatzidionysiou K., Sfikakis P.P. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. RMD Open. 2019;5(2):e000993. Published 2019 Jul 27. DOI: 10.1136/rmdopen-2019-000993Doria A., Zavaglia D. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review. Clin Exp Rheumatol. 2019;37(5):862–871.Doria A., Zavaglia D. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review. Clin Exp Rheumatol. 2019;37(5):862–871.Choy E., Aletaha D., Behrens F., et al. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology (Oxford). 2017;56(5):689–697. DOI: 10.1093/rheumatology/kew271Choy E., Aletaha D., Behrens F., et al. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology (Oxford). 2017;56(5):689–697. DOI: 10.1093/rheumatology/kew271Насонов Е.Л., Олюнин Ю.А., Лила А.М. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263–271. DOI: 10.14412/1995-4484-2018-263-271Nasonov E.L., Olyunin Yu.A., Lila A.M. Rheumatoid arthritis: the problems of remission and therapy resistance. Rheumatology Science and Practice. 2018;56(3):263–271 (In Russ.). DOI: 10.14412/1995-4484-2018-263-271Oray M., Abu Samra K., Ebrahimiadib N., et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–465. DOI: 10.1517/14740338.2016.1140743Oray M., Abu Samra K., Ebrahimiadib N., et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–465. DOI: 10.1517/14740338.2016.1140743Gianfrancesco M., Hyrich K.L., Al-Adely S., et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. DOI: 10.1136/annrheumdis-2020-217871Gianfrancesco M., Hyrich K.L., Al-Adely S., et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. DOI: 10.1136/annrheumdis-2020-217871Takeuchi T., Genovese M.C., Haraoui B., et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019;78(2):171–178. DOI: 10.1136/annrheumdis-2018-213271Takeuchi T., Genovese M.C., Haraoui B., et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019;78(2):171–178. DOI: 10.1136/annrheumdis-2018-213271Schwartz D.M., Bonelli M., Gadina M., O’Shea J.J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36. DOI: 10.1038/nrrheum.2015.167Schwartz D.M., Bonelli M., Gadina M., O’Shea J.J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36. DOI: 10.1038/nrrheum.2015.167Firestein G.S., McInnes I.B. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–196. DOI: 10.1016/j.immuni.2017.02.006Firestein G.S., McInnes I.B. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–196. DOI: 10.1016/j.immuni.2017.02.006Sornasse T., Sokolove J., McInnes I. Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/treatment-with-upadacitinib-results-in-the-normalization-ofkey-pathobiologic-pathways-in-patients-with-rheumatoidarthritis/. Accessed August 21, 2020.Sornasse T., Sokolove J., McInnes I. Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/treatment-with-upadacitinib-results-in-the-normalization-ofkey-pathobiologic-pathways-in-patients-with-rheumatoidarthritis/. Accessed August 21, 2020.Lent S., Sornasse T., Georgantas R., Sokolove J., McInnes I. Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/molecular-analysis-of-the-mode-of-action-of-upadacitinib-inrheumatoid-arthritis-patients-whole-blood-rna-expression-datafrom-the-select-next-study.Lent S., Sornasse T., Georgantas R., Sokolove J., McInnes I. Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/molecular-analysis-of-the-mode-of-action-of-upadacitinib-inrheumatoid-arthritis-patients-whole-blood-rna-expression-datafrom-the-select-next-study.Sornasse T., Song I.H., Radstake T., et al. [FRI0026]. Proteomics analysis comparing the mode of action of upadacitinib and adalimumab head to head in ra identifies novel, discrete early immune pathway modulation in the SELECT-COMPARE phase 3 study. Ann Rheum Dis. 2020;79:585–586. DOI: 10.1136/annrheumdis-2020-eular.1908Sornasse T., Song I.H., Radstake T., et al. [FRI0026]. Proteomics analysis comparing the mode of action of upadacitinib and adalimumab head to head in ra identifies novel, discrete early immune pathway modulation in the SELECT-COMPARE phase 3 study. Ann Rheum Dis. 2020;79:585–586. DOI: 10.1136/annrheumdis-2020-eular.1908

The authors declare that there are no conflicts of interest present.